SCHEMBL9760097

SCHEMBL9760097

COc1c(-c2ccccc2)c(=O)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.53
PDE4A P27815 5/20 0.53
PDE4C Q08493 5/20 0.53
PDE4D Q08499 5/20 0.53
MAPT P10636 5/20 0.52
HTT P42858 2/20 0.52
LMNA P02545 1/20 0.52
ABCG2 Q9UNQ0 3/20 0.47
ALDH1A1 P00352 7/20 0.45
CYP3A4 P08684 3/20 0.45
MITF O75030 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 4/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
ABCC1 P33527 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324941 0.93 PDE4B (0.55) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL9509519 0.83 MAPT (0.48) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL12181771 0.79 PDE4B (0.71) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL3943393 0.78 MAPT (0.46) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL9760352 0.78 LMNA (0.46) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL8640682 0.78 LMNA (0.46) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL3743073 0.77 ALDH1A1 (0.44) MAPTHTTALDH1A1CYP3A4SMN1; SMN2
SCHEMBL18392174 0.75 HTT (0.88) MAPTHTTLMNAALDH1A1KDM4E
SCHEMBL9554998 0.74 LTA4H (0.49) MAPTHTTLMNAALDH1A1CYP2C9
SCHEMBL10967156 0.72 LMNA (0.62) MAPTHTTLMNAALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080009485-A1 Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis WYETH (US) 2008-01-10 US disclosed
US-4986935-A NONLINEAR OPTICAL DEVICES; COMPOUND HAVING HIGH ACTIVITY FOR SECOND HARMONIC WAVE GENERATION FUJI XEROX CO., LTD. (JP) 1991-01-22 US disclosed
US-4751327-A Photoconductive imaging members with unsymmetrical squaraine compounds XEROX CORPORATION (US) 1988-06-14 US disclosed
US-4624904-A Photoconductive imaging members with unsymmetrical squaraine compounds containing an hydroxyl group XEROX CORPORATION (US) 1986-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009485-A1 Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis PLA2G12A, PLA2G1B, PLA2G5 PDE4B 220/4885PDE4A 238/4885PDE4C 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.